Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Evaluate the Safety and Tolerability of Monoclonal Antibody EP0089 in Patients With Advanced Solid Tumours

NCT07030478 is registered in ClinicalTrials.gov with Ellipses Pharma as lead sponsor.

NCT NCT07030478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07030478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Evaluate the Safety and Tolerability of Monoclonal Antibody EP0089 in Patients With Advanced Solid Tumours
Lead sponsor
Ellipses Pharma
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
June 30, 2029
Enrollment
190 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancers, solid tumours